Want to see AU:EXL full AI Analyst Report?
EXL Stock Chart & Stats
AU$0.02
<AU$0.01(16.67%)
At close: 4:00 PM EDT
AU$0.02
<AU$0.01(16.67%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume100.00K
Average Volume (3M)5.59M
Market Cap
AU$3.51M
Enterprise ValueAU$5.52
Total Cash (Recent Filing)AU$996.00K
Total Debt (Recent Filing)AU$4.03M
Price to Earnings (P/E)―
Beta-1.10
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding438,198,640
10 Day Avg. Volume15,329,612
30 Day Avg. Volume5,590,708
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.15
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Higher-margin Channel Mix And Structural Cost ReductionThe shift toward direct e-commerce and away from low-margin bulk sales should improve gross-margin quality and revenue control. A structurally lower operating-cost base also reduces the sales scale required to approach sustainable profitability.
Direct-to-consumer Growth And Product InnovationStrong D2C growth can deepen customer relationships, reduce dependence on major wholesalers and support better economics. Continued product launches broaden the portfolio and create opportunities to participate in expanding wellness and functional-food categories.
Established Hemp Platform And Contracted SupplyA recognized hemp position, vertical integration and contracted supply may provide product availability and private-label opportunities as demand develops. These capabilities can support brand credibility and more consistent execution across consumer and trade channels.
Bears Say
Persistent Losses And Negative Cash GenerationThe business has not yet demonstrated self-funded operations despite lower cash burn and a positive Q4. Continued losses and cash outflows increase reliance on financing, constrain investment capacity and make the turnaround dependent on sustained execution.
Balance-sheet Deterioration And Reduced FlexibilityHigher debt alongside declining equity and assets weakens the financial cushion while profitability remains unproven. Although the capital raise adds liquidity, the company may still face limited flexibility if the turnaround requires further funding.
Regulatory, Channel And Concentration RisksRegulatory uncertainty can restrict the U.S. CBD addressable market and complicate investment decisions. Supermarket pressure and heavy reliance on three brands further increase exposure to channel changes, product reprioritization or weakness in a key franchise.
Elixinol Wellness News
EXL FAQ
What was Elixinol Wellness’s price range in the past 12 months?
Elixinol Wellness lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Elixinol Wellness’s market cap?
Elixinol Wellness’s market cap is AU$3.51M.
When is Elixinol Wellness’s upcoming earnings report date?
Elixinol Wellness’s upcoming earnings report date is Feb 19, 2027 which is in 165 days.
How were Elixinol Wellness’s earnings last quarter?
Elixinol Wellness released its earnings results on Aug 31, 2026. The company reported -AU$0.003 earnings per share for the quarter.
Is Elixinol Wellness overvalued?
According to Wall Street analysts Elixinol Wellness’s price is currently Overvalued.
Does Elixinol Wellness pay dividends?
Elixinol Wellness does not currently pay dividends.
What is Elixinol Wellness’s EPS estimate?
Elixinol Wellness’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elixinol Wellness have?
Elixinol Wellness has 438,198,640 shares outstanding.
What happened to Elixinol Wellness’s price movement after its last earnings report?
Elixinol Wellness reported an EPS of -AU$0.003 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Elixinol Wellness?
Currently, no hedge funds are holding shares in AU:EXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elixinol Wellness Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EXL Sentiment 60%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elixinol Wellness
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp-derived products, encompassing nutraceuticals, cosmetics, and various food items. These products are marketed under its distinct brands, Elixinol and Hemp Foods Australia, reaching consumers across the Americas, Europe, and Australia. Its extensive product range features hemp-derived cannabidiol (CBD) items, food products, dietary supplements, and topical skincare solutions. Notably, the company transitioned to its current name in May 2021, having previously been known as Elixinol Global Limited.
Technical Analysis
Cann Group
―
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―